Patents by Inventor Michelle Schmidt
Michelle Schmidt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240327626Abstract: A rubber composition suited to forming a tire ply includes 100 phr of elastomer, at least 30 phr of an intermediate carbon black, at least 5 phr silica, such as high surface area silica particles, at least 0.1 phr of a tear strength agent, a sulfur-based curing agent, and an accelerator for the curing agent. The elastomer incudes 60-100 phr of a conjugated diene elastomer. The intermediate carbon black has a statistical thickness surface area (STSA) of from 50 m2/g to 70 m2/g.Type: ApplicationFiled: March 29, 2023Publication date: October 3, 2024Inventors: Dawn Michelle Johnson, Carolin Anna Welter, Ryan Michael Schmidt
-
Publication number: 20240273552Abstract: A data management system that operates to receive high level data of categories for a corpus of entities, the high level data indicating characteristics of the corpus of entities that indicate emissions production of each entity of the corpus of entities. The data management system operates to select one or more modeling assumptions for the categories, the one or more modeling assumptions modeling low level consumption data based on the high level data and generate emissions indicators for each of the categories for each entity of the corpus of entities for a plurality of points in time based on the high level data and the one or more modeling assumptions. The data management system operates to sort the emissions indicators into a plurality of buckets based on the categories and generate data causing a computing device to display the emissions indicators sorted into the plurality of buckets.Type: ApplicationFiled: June 14, 2022Publication date: August 15, 2024Applicant: U.S. Venture, Inc.Inventors: Jeffrey Lang, John A. Schmidt, Michelle Lynn Richard, Lisa Ann Knuth
-
Publication number: 20200079785Abstract: The present invention provides MMC prodrug compounds and liposomal MMC prodrugs and compositions thereof for the treatment of cancer. The compositions include liposomes containing a phosphatidylcholine lipid, a sterol, a PEG-lipid and a MMC prodrug. The present invention also provides liposomal compositions for the treatment of cancer comprising administering to a patient in need thereof a liposome, wherein the liposome comprises: a phosphatidylcholine lipid; a sterol; a PEG-lipid and a MMC prodrug or a pharmaceutically-acceptable salt thereof.Type: ApplicationFiled: November 8, 2017Publication date: March 12, 2020Applicant: Mallinckrodt LLCInventors: William McGHEE, Michelle SCHMIDT, Margaret GRAPPERHAUS, Kah Tiong KUAN
-
Publication number: 20200008562Abstract: A size-adjustable wearable device stores and protects items, such as rings, for example. The wearable device can be designed to securely hold items, including valuables, such as rings, in a manner that allows for peace of mind and convenience while the wearer goes about a variety of different activities. The wearer can expose a storage chamber in the device by opening a cover on the underside of a band. The ring, jewelry, or other valuable can be deposited inside the storage chamber, and the cover can be placed securely over the top of the storage chamber. The wearer can then strap the band on their person. The band can be worn with the cover disposed securely and tightly against the person, thus providing an additional level of security. In some embodiments, the storage chamber can include arms to further help secure an item, such as a ring, there within.Type: ApplicationFiled: June 6, 2019Publication date: January 9, 2020Inventors: Michelle SCHMIDT, John SCHMIDT
-
Publication number: 20140271465Abstract: The present invention provides compound conjugates of matrix metalloprotease inhibitors and linked metal chelators which are useful for imaging solid tumors and treating and diagnosing certain types of diseases such as cancer.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: Mallinckrodt LLCInventors: John N. Freskos, Mary Dyszlewski, Lori Chinen, Hector Knight, Michelle Schmidt
-
Publication number: 20090227634Abstract: The invention relates to compounds of formula (I) processes for their preparation, their use as 5-lipoxygenase inhibitors and pharmaceutical compositions containing the same.Type: ApplicationFiled: November 24, 2008Publication date: September 10, 2009Inventors: Edgardo Alvira, Matthew J. Graneto, Margaret Lanahan Grapperhaus, Kaliappan Iyanar, Todd M. Maddux, Matthew W. Mahoney, Mark A. Massa, Kirby R. Sample, Michelle A. Schmidt, Ronald E. Seidel, Jon G. Selbo, Michael B. Tollefson, Richard A. Vonder Embse, Grace M. Wagner, Scott S. Woodard
-
Patent number: 7119203Abstract: This invention is directed generally to proteinase (also known as “protease”) inhibitors, and, more particularly, to piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids that, inter alia, inhibit matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. Such hydroxamic acids generally correspond in structure to the following formula: (wherein A1, A2, Y, E1, E2, E3, and Rx are as defined in this specification), and further include salts of such compounds. This invention also is directed to compositions of such hydroxamic acids, intermediates for the syntheses of such hydroxamic acids, methods for making such hydroxamic acids, and methods for treating conditions (particularly pathological conditions) associated with MMP activity and/or aggrecanase activity.Type: GrantFiled: April 25, 2003Date of Patent: October 10, 2006Assignee: Pharmacia CorporationInventors: Thomas E. Barta, Daniel P. Becker, Louis J. Bedell, Terri L. Boehm, David L. Brown, Jeffery N. Carroll, Yiyuan Chen, Yvette M. Fobian, John N. Freskos, Alan F. Gasiecki, Margaret L. Grapperhaus, Robert M. Heintz, Susan L. Hockerman, Darren J. Kassab, Ish K. Khanna, Stephen A. Kolodziej, Mark A. Massa, Joseph J. McDonald, Brent V. Mischke, Deborah A. Mischke, Patrick B. Mullins, Mark A. Nagy, Monica B. Norton, Joseph G. Rico, Michelle A. Schmidt, Nathan W. Stehle, John J. Talley, William F. Vernier, Clara I. Villamil, Lijuan J. Wang, Thomas A. Wynn
-
Publication number: 20060074243Abstract: This invention is directed generally to hydroxamic acid and amide compounds (including salts of such compounds), and, more particularly, to aryl- and heteroaryl-arylsulfonylmethyl hydroxamic acids and amides that, inter alia, inhibit protease activity, particularly matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. These compounds generally correspond in structure to Formula I: wherein A1, A2, A3, E1, E2, E3, and E4 are as defined in this patent. This invention also is directed to compositions of such compounds, intermediates for the syntheses of such compounds, methods for making such compounds, and methods for treating conditions associated with MMP activity and/or aggrecanase activity, particularly pathological conditions.Type: ApplicationFiled: November 10, 2005Publication date: April 6, 2006Inventors: Daniel Becker, Yiyuan Chen, John Freskos, Alan Gasiecki, Margaret Grapperhaus, Donald Hansen, Robert Heintz, Darren Kassab, Ish Khanna, Stephen Kolodziej, Sergio Mantegani, Mark Massa, Joseph McDonald, Deborah Mischke, Mark Nagy, Ettore Perrone, Joseph Rico, Michelle Schmidt, Dale Spangler, John Talley, Mahima Trivedi, Thomas Wynn
-
Patent number: 7015306Abstract: Peptide analogs of neurotensin are disclosed which are resistant to enzymatic degradation and which retain high binding affinity for neurotensin receptors. Pharmaceutical compositions of these compounds are useful for diagnostic and therapeutic purposes.Type: GrantFiled: December 21, 2001Date of Patent: March 21, 2006Assignee: BioSynthema, Inc.Inventors: Ananthachari Srinivasan, Jack L. Erion, Michelle A. Schmidt
-
Publication number: 20050209278Abstract: This invention is directed generally to proteinase (also known as “protease”) inhibitors, and, more particularly, to piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids that, inter alia, inhibit matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. Such hydroxamic acids generally correspond in structure to the following formula: (wherein A1, A2, Y, E1, E2, E3, and Rx are as defined in this specification), and further include salts of such compounds. This invention also is directed to compositions of such hydroxamic acids, intermediates for the syntheses of such hydroxamic acids, methods for making such hydroxamic acids, and methods for treating conditions (particularly pathological conditions) associated with MMP activity and/or aggrecanase activity.Type: ApplicationFiled: November 3, 2003Publication date: September 22, 2005Inventors: Joseph McDonald, Darren Kassab, Mark Massa, Margaret Grapperhaus, Michelle Schmidt, Joseph Rico, Patrick Mullins, David Brown
-
Publication number: 20050191240Abstract: Peptide analogs of neurotensin are disclosed which are resistant to enzymatic degradation and which retain high binding affinity for neurotensin receptors. Pharmaceutical compositions of these compounds are useful for diagnostic and therapeutic purposes.Type: ApplicationFiled: December 21, 2001Publication date: September 1, 2005Inventors: Ananthachari Srinivasan, Jack Erion, Michelle Schmidt
-
Publication number: 20050009838Abstract: This invention is directed generally to proteinase (also known as “protease”) inhibitors, and, more particularly, to piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids that, inter alia, inhibit matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. Such hydroxamic acids generally correspond in structure to the following formula: (wherein A1, A2, Y, E1, E2, E3, and Rx are as defined in this specification), and further include salts of such compounds. This invention also is directed to compositions of such hydroxamic acids, intermediates for the syntheses of such hydroxamic acids, methods for making such hydroxamic acids, and methods for treating conditions (particularly pathological conditions) associated with MMP activity and/or aggrecanase activity.Type: ApplicationFiled: April 25, 2003Publication date: January 13, 2005Inventors: Thomas Barta, Daniel Becker, Louis Bedell, Terri Boehm, David Brown, Jeffery Carroll, Yiyuan Chen, Yvette Fobian, John Freskos, Alan Gasiecki, Margaret Grapperhaus, Robert Heintz, Susan Hockerman, Darren Kassab, Ish Khanna, Stephen Kolodziej, Mark Massa, Joseph McDonald, Brent Mischke, Deborah Mischke, Patrick Mullins, Mark Nagy, Monica Norton, Joseph Rico, Michelle Schmidt, Nathan Stehle, John Talley, William Vernier, Clara Villamil, Lijuan Wang, Thomas Wynn
-
Publication number: 20040167182Abstract: This invention is directed generally to hydroxamic acid and amide compounds (including salts of such compounds), and, more particularly, to aryl- and heteroaryl-arylsulfonylmethyl hydroxamic acids and amides that, inter alia, inhibit protease activity, particularly matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity.Type: ApplicationFiled: June 25, 2003Publication date: August 26, 2004Inventors: Daniel P. Becker, Yiyuan Chen, John N. Freskos, Alan F. Gasiecki, Margaret L. Grapperhaus, Donald W. Hansen, Robert M. Heintz, Darren J. Kassab, Ish K. Khanna, Stephen A. Kolodziej, Sergio Mantegani, Mark A. Massa, Joseph J. McDonald, Deborah A. Mischke, Mark A. Nagy, Ettore Perrone, Joseph G. Rico, Michelle A. Schmidt, Dale P. Spangler, John J. Talley, Mahima Trivedi, Thomas A. Wynn
-
Publication number: 20040142979Abstract: This invention is directed generally to heteroarylsulfonylmethyl hydroxamic acids and amides that, inter alia, tend to inhibit protease activity, particularly matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. This invention also is directed to compositions of such compounds; intermediates for the syntheses of such compounds; methods for making such compounds; and methods for treating conditions associated with MMP, tumor necrosis factors (or “TNFs”), and/or aggrecanase activity, particularly pathological conditions.Type: ApplicationFiled: November 25, 2003Publication date: July 22, 2004Inventors: Daniel P. Becker, Jeffery N. Carroll, Yvette M. Fobian, Margaret L. Grapperhaus, Donald W. Hansen, Robert M. Heintz, Darren J. Kassab, Mark A. Massa, Joseph J. McDonald, Mark A. Nagy, Barnett S. Pitzele, Joseph G. Rico, Michelle A. Schmidt, Dale P. Spangler
-
Publication number: 20040106548Abstract: Conformational constraints in diagnostic and therapeutic agents in peptides have been introduced by utilization of disulfide bonds and amide cyclizations. These constraints are responsible for altering the stability and specificity of these receptor-targeted agents. Conformationally constrained peptides containing secondary and primary amines, ethers, thioethers, amidines, esters and other functionalities have been synthesized. Methods are disclosed which incorporate multiple features of the above functionalities in the macrocyclic ring of the peptides.Type: ApplicationFiled: July 11, 2003Publication date: June 3, 2004Inventors: Michelle A Schmidt, Jack L Erion, Ananthachari Srinivasan
-
Patent number: 6132697Abstract: A radiopharmaceutical capable of localizing at a site of thrombus containing activated platelets within a mammalian body is provided wherein the radiopharmaceutical comprises a linear peptidomimetic containing ligand capable of specifically binding to the GPIIb/IIIa integrin receptor of platelets in the thrombus and a radionuclide covalently bound to the peptidomimetic containing ligand. The ligand compositions of the invention are provided complexed with a selected metal radionuclide to form a diagnostic or therapeutic radiopharmaceutical to image a site of thrombus or provide radiotherapy to the site of thrombus, respectively.Type: GrantFiled: June 5, 1997Date of Patent: October 17, 2000Assignee: G. D. Searle & Co.Inventors: Ananthachari Srinivasan, Larry P. Feigen, Daniel Lee Flynn, Jeffery Alan Zablocki, Philip Needleman, Michelle A. Schmidt
-
Patent number: D624972Type: GrantFiled: November 9, 2009Date of Patent: October 5, 2010Inventor: Michelle Schmidt